The prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy-Reference-Cited by-同舟云学术

The prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy

Published:2022-01 Issue:1 Volume:41 Page:3-10
ISSN:2253-8089
Container-title:Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
language:en
Short-container-title:Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Author:

Can Canan,Akdeniz Nadiye,Kömek Halil,Gündoğan Cihan,Urakçı Zuhat,Işıkdoğan Abdurrahman

Publisher

Elsevier BV

Reference22 articles.

1. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer;Buzdar;J Clin Oncol.,2005

2. Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast?;Chaturvedi;Breast Cancer Res Treat.,2005

3. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol.,2012

4. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer;Chollet;Br J Cancer.,2002

5. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy;Gonzalez-Angulo;J Clin Oncol.,2005

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular imaging as biomarker for treatment response and outcome in breast cancer;Therapeutic Advances in Medical Oncology;2023-01

2. The Value of 18F-FDG PET/CT Imaging in the Evaluation of Interim Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer;Molecular Imaging and Radionuclide Therapy;2022-06-01